Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance

Biomedicine and Pharmacotherapy

Volumn 64, Issue 8, 2010, Pages 550-558

  Zuo, Qiang ^a   Shi, Min ^a   Li, Libo ^a   Chen, Jinzhang ^a   Luo, Rongcheng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Cetuximab; Drug resistance; IGF 1R; Nasopharyngeal carcinoma; PTEN; Ras

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GLYCOPROTEIN P; K RAS PROTEIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SHORT HAIRPIN RNA; SOMATOMEDIN C RECEPTOR; SURVIVIN;

ARTICLE; CANCER CELL CULTURE; CODON; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; EXON; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION; GENES, RAS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NASOPHARYNGEAL NEOPLASMS; PLASMIDS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 77956882253     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.03.003     Document Type: Article

References (52)

1. Wang Y., Minoshima S., Shimizu N. Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved fish technique. Jpn J Hum Genet 1993, 38:399-406.
2. Chua D.T., Nicholls J.M., Sham J.S., Au G.K. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59:11-20.
3. Raoul J.L., Van Laethem J.L., Peeters M., Brezault C., Husseini F., Cals L., et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 2009, 9:112.
4. Jean G.W., Shah S.R. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 2008, 28:742-754.
5. Hebbar M., Fournier P., Romano O. KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?. Eur J Cancer Care (Engl) 2009, [Epub ahead of print].
6. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
7. Normanno N., Tejpar S., Morgillo F., De Luca A., Van Cutsem E., Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009, 6:519-527.
8. Chan A.T., Hsu M.M., Goh B.C., Hui E.P., Liu T.W., Millward M.J., et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005, 23:3568-3576.
9. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
10. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127.
11. Van Cutsem E., Oliveira J. Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):49-50.
12. Dassonville O., Formento J.L., Francoual M., Ramaioli A., Santini J., Schneider M., et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993, 11:1873-1878.
13. Rubin Grandis J., Melhem M.F., Barnes E.L., Tweardy D.J. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996, 78:1284-1292.
14. Ang K.K., Andratschke N.H., Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 2004, 58:959-965.
15. Rubin Grandis J., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998, 90:824-832.
16. Egloff A.M., Grandis J.R. Improving response rates to EGFR-targeted therapies for head and neck squamous cell carcinoma: candidate predictive biomarkers and combination treatment with Src inhibitors. J Oncol 2009, 2009:896407.
17. Ma B.B., Poon T.C., To K.F., Zee B., Mo F.K., Chan C.M., et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study. Head Neck 2003, 25:864-872.
18. Coutinho C.M., Bassini A.S., Gutierrez L.G., Butugan O., Kowalski L.P., Brentani M.M., et al. Genetic alterations in Ki-ras and Ha-ras genes in juvenile nasopharyngeal angiofibromas and head and neck cancer. Sao Paulo Med J 1999, 117:113-120.
19. Meriggi F., Di Biasi B., Abeni C., Zaniboni A. Anti-EGFR therapy in colorectal cancer: how to choose the right patient. Curr Drug Targets 2009, 10:1033-1040.
20. Molinari F., Martin V., Saletti P., De Dosso S., Spitale A., Camponovo A., et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 2009, 100:1087-1094.
21. Bouali S., Chretien A.S., Ramacci C., Rouyer M., Becuwe P., Merlin J.L. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Oncol Rep 2009, 21:731-735.
22. Urasaki Y., Laco G.S., Pourquier P., Takebayashi Y., Kohlhagen G., Gioffre C., et al. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res 2001, 61:1964-1969.
23. Stein U., Walther W. Cytokine-mediated reversal of multidrug resistance. Cytotechnology 1998, 27:271-282.
24. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
25. Jones H.E., Goddard L., Gee J.M., Hiscox S., Rubini M., Barrow D., et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004, 11:793-814.
26. Kokubo Y., Gemma A., Noro R., Seike M., Kataoka K., Matsuda K., et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005, 92:1711-1719.
27. She Q.B., Solit D., Basso A., Moasser M.M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res 2003, 9:4340-4346.
28. Toker A., Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res 2006, 66:3963-3966.
29. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004, 30:193-204.
30. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A.overcome PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
31. Fujita T., Doihara H., Kawasaki K., Takabatake D., Takahashi H., Washio K., et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 2006, 94:247-252.
32. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
33. Park B.H., Davidson N.E. PI3 kinase activation and response to trastuzumab therapy: what's new with herceptin resistance?. Cancer Cell 2007, 12:297-299.
34. Frattini M., Saletti P., Romagnani E., Martin V., Molinari F., Ghisletta M., et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007, 97:1139-1145.
35. Wang M.Y., Lu K.V., Zhu S., Dia E.Q., Vivanco I., Shackleford G.M., et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006, 66:7864-7869.
36. Wendel H.G., Malina A., Zhao Z., Zender L., Kogan S.C., Cordon-Cardo C., et al. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 2006, 66:7639-7646.
37. Mellinghoff I.K., Cloughesy T.F., Mischel P.S. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2007, 13:378-381.
38. Lu C.H., Wyszomierski S.L., Tseng L.M., Sun M.H., Lan K.H., Neal C.L., et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007, 13:5883-5888.
39. Chou C.C., Chou M.J., Tzen C.Y. PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival. Med Oncol 2009, 26:322-326.
40. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689.
41. Weiss B., Bollag G., Shannon K., Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet 1999, 89:14-22.
42. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565.
43. Simpson L., Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res 2001, 264:29-41.
44. Zimmermann S., Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999, 286:1741-1744.
45. Hannon G.J. RNA interference. Nature 2002, 418:244-251.
46. Sarela A.I., Macadam R.C., Farmery S.M., Markham A.F., Guillou P.J. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000, 46:645-650.
47. Ito T., Shiraki K., Sugimoto K., Yamanaka T., Fujikawa K., Ito M., et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000, 31:1080-1085.
48. Shin S., Sung B.J., Cho Y.S., Kim H.J., Ha N.C., Hwang J.I., et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001, 40:1117-1123.
49. Mesri M., Morales-Ruiz M., Ackermann E.J., Bennett C.F., Pober J.S., Sessa W.C., et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001, 158:1757-1765.
50. Notarbartolo M., Cervello M., Poma P., Dusonchet L., Meli M., D'Alessandro N. Expression of the IAPs in multidrug resistant tumor cells. Oncol Rep 2004, 11:133-136.
51. Nakamura M., Tsuji N., Asanuma K., Kobayashi D., Yagihashi A., Hirata K., et al. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients. Cancer Sci 2004, 95:44-51.
52. Grossman D., Altieri D.C. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001, 20:3-11.